| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04360551 Details | 2023-08-21 Interventional | 2 | 24 | Telmisartan COVID-19 | Decrease in COVID-19 cases locally The number of individuals involved in the study was extremely small. The study was terminated early because the number of infections in the community substantially decreased. As an outpatient study, the study only involved individuals with mild to moderate COVID-19 infection, as those severely ill with acute COVID-19 infections may have been hospitalized. | |||
| NCT04227275 Details | 2023-08-21 Interventional | 1 | 16 | Cyclophosphamid… Fludarabine Interleukin 1 R… Prostatic Neopl… Metastatic Cast… | Based on the safety events and evidence of biologic activity without sustained clinical
responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has
terminated the study. - | |||
| NCT04119336 Details | 2023-08-21 Interventional | 2 | 2 | Cyclophosphamid… Dexamethasone Ixazomib Nivolumab Multiple Myelom… Neoplasms, Plas… Refractory Mult… Relapsed Multip… | Study closure initiated by industry funding sponsor for commercial reasons. - | |||
| NCT03901612 Details | 2023-08-21 Interventional | 4 | 0 | Ropivacaine Post Operative … | covid and surgeon left - | |||
| NCT03626545 2018-002480-26 Details | 2023-08-21 Interventional | 3 | 245 | Docetaxel Carcinoma, Non-… Lung Neoplasms Non-Small-Cell … | The study was early terminated due to the lack of efficacy of study treatment observed in the
analysis of the primary endpoint of the randomized part - | |||
| NCT02647892 Details | 2023-08-21 Interventional | 4 | 70 | Lidocaine Local Anesthesi… | IRB protocol administratively closed, Continuing Review or Study Completion Report not
submitted - | |||
| NCT05677373 Details | 2023-08-18 Interventional | 1/2 | 0 | Trametinib Melanoma Uveal Neoplasms Advanced Uveal … Metastatic Uvea… Unresectable Uv… | The drug company supporting this trial has withdrawn support, including the ability to provide
study agent. - | |||
| NCT05221749 Details | 2023-08-18 Interventional | 3 | 50 | Fluorides Communicable Di… Dental Caries Infections Caries Dental Caries i… Microbial Colon… Primary Teeth | Only the 1 month follow-up was completed. The principal investigator could not complete the 3
month follow-up appointments and was not calibrated with other dentists who were available at
the time. - | |||
| NCT05063734 2020-000362-42 Details | 2023-08-18 Interventional | 2 | 16 | Aflibercept Diabetic Retino… Edema Macular Edema Diabetes Mellit… Diabetic Macula… | Based on data obtained in Part A, there was insufficient evidence of efficacy on the key
outcome measures. As a result, the study was not advanced to Part B. Based on data obtained in Part A, there was insufficient evidence of efficacy on the key outcome measures. As a result, the study was not advanced to Part B | |||
| NCT04647084 Details | 2023-08-18 Interventional | 4 | 0 | Lidocaine Acute Pain Pain, Acute Patient Satisfa… | The investigators were unable to begin work on this study. - | |||
| NCT03713801 Details | 2023-08-18 Interventional | 1 | 18 | Metformin Aging Vaccine Respons… | Study has been halted due to COVID-19 pandemic, immunity of the subject has been a concern.
Modifications are planned for the protocol. - | |||
| NCT05131204 2020-002761-33 Details | 2023-08-16 Interventional | 3 | 2 | Eculizumab Ravulizumab Hemoglobinuria Hemoglobinuria,… Paroxysmal Noct… | Sponsor decision not related to efficacy or safety. - | |||
| NCT05106335 Details | 2023-08-16 Interventional | 3 | 1 | Docetaxel Advanced NSCLC | Sponsor R & D Strategy Adjustment - | |||
| NCT03377725 Details | 2023-08-16 Interventional | 3 | 0 | Arsenic Trioxid… Decitabine Myelodysplastic… Preleukemia Syndrome P53 Mutation | No patient was involved. - | |||
| NCT01982760 Details | 2023-08-16 Interventional | 2 | 14 | Deamino Arginin… Ecchymosis Postoperative E… | - - | |||
| NCT01465100 Details | 2023-08-16 Interventional | 1/2 | 1 | Liver Extracts Phenylketonuria… Phenylketonuria | Study was funded by NIH grant; grant funding ended in June 2023 without enrollment of
additional subjects; the only subject enrolled was in 2011. - | |||
| NCT01011478 Details | 2023-08-16 Interventional | 3 | [1 Refs] | 406 | Rosuvastatin Ca… Colonic Neoplas… Precancerous Co… Colorectal Canc… Precancerous Co… | - Early termination leading to small numbers of subjects analyzed. | ||
| NCT05993143 Details | 2023-08-15 Interventional | 3 | 249 | Ivermectin COVID-19 SARS-CoV-2 | Study was stopped because no statistically significant difference was observed in the interim
analysis. With high vaccine rates in those over 50 and an expected low incidence, it would not
be feasible to complete recruitment within a short period. - | |||
| NCT05510427 Details | 2023-08-15 Interventional | 1 | 0 | Atezolizumab Bevacizumab Infigratinib Cholangiocarcin… Liver Cancer | Per PI's request - | |||
| NCT05205252 Details | 2023-08-15 Interventional | 1/2 | 0 | Acalabrutinib Antibodies, Mon… Daratumumab Dexamethasone Lenalidomide Pomalidomide Tyrosine Kinase… Hematologic Neo… Neoplasms Refractory Hema… Relapsed Hemato… | Epizyme Inc. has revised the Tazemetostat development strategy and made the decision to
terminate the hematological malignancies basket trial. - |